Exploring new ways to lower triglycerides for heart disease prevention
Genetics and Triglycerides: opportunities for new approaches to identify therapies
This study is looking at how lowering triglyceride levels might help reduce the risk of heart disease by exploring new ways to target specific genes, and it's for anyone interested in better heart health and new treatments for managing triglycerides.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11092727 on NIH RePORTER |
What this research studies
This research investigates how lowering triglyceride (TG) levels can reduce the risk of coronary heart disease (CHD) by exploring new drug targets beyond the traditional lipoprotein lipase (LPL) pathway. It aims to understand the long-term effects of targeting specific TG genes and their potential impacts on various health conditions. By using a Mendelian randomization approach, the study will analyze genetic variations to identify clinical phenotypes associated with TG gene function. This could lead to the development of more effective therapies for managing triglyceride levels and improving overall heart health.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals under 20 years of age, particularly those of African descent, who may have genetic variations affecting triglyceride metabolism.
Not a fit: Patients over the age of 20 or those without genetic variations related to triglyceride metabolism may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively lower triglyceride levels and reduce the risk of heart disease, particularly for at-risk populations.
How similar studies have performed: Previous research has shown promise in targeting triglyceride levels for heart disease prevention, but this approach of using genetic variations to identify new drug targets is relatively novel.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Feng, Qiping — Vanderbilt University Medical Center
- Study coordinator: Feng, Qiping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.